NCT02646475View on ClinicalTrials.gov

Metabolic Effects of Angiotensin-(1-7)

PHASE1RecruitingINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

December 31, 2029

Study Completion Date

December 31, 2029

Conditions
ObesityInsulin ResistanceHypertensionMetabolic Cardiovascular Syndrome
Interventions
DRUG

Angiotensin-(1-7)

This is a biologically active endogenous angiotensin peptide. It may play an important role in the regulation of blood pressure by dilating blood vessels as well as a role in the regulation of insulin action.

DRUG

Saline

Normal saline will be used as a placebo comparator.

Trial Locations (1)

37232

RECRUITING

Vanderbilt University Medical Center, Nashville

All Listed Sponsors
lead

Vanderbilt University

OTHER